Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

NCT03225664 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Unresectable Lung Non-Small Cell Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
OTHER: Pharmacokinetic Study
DRUG: Trametinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]